Can transrectal prostate ultrasound compete with multiparametric MRI in the detection of clinically significant prostate cancer?

Autor:	Grey ADR; Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.; Division of Surgical and Interventional Sciences, Faculty of Medicine, University College London, London, UK.; Department of Urology, Barts and The Royal London Hospitals, London, UK.; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK., Connor MJ; Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK., Tam J; Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK., Loch T; Department of Urology Diakonissenkrankenhaus, Flensburg, University Teaching Hospital of Christian-Albrechts-Universität Kiel, Flensburg, Germany.
Jazyk:	angličtina
Zdroj:	Translational andrology and urology [Transl Androl Urol] 2020 Jun; Vol. 9 (3), pp. 1492-1500.
DOI:	10.21037/tau.2020.02.26
Abstrakt:	We consider the current and future role of transrectal ultrasound imaging in the diagnosis of prostate cancer, with a particular focus on the pre-biopsy localization and targeting role that multiparametric MRI (mpMRI) has come to occupy for some men in recent years. We draw a distinction between transrectal ultrasound (TRUS) used only as a means of distributing zonal biopsies with its employment as a means for identifying and targeting sonographically abnormal lesions. The role of AI in lesion identification and targeting will be reviewed. Comparisons of cost and availability, frequency of contraindications and diagnostic accuracy between these two imaging modalities will be drawn. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.02.26). The series “Prostate Imaging and Focal Therapy” was commissioned by the editorial office without any funding or sponsorship. MJC served as the unpaid Guest Editor of the series. ADR Grey has received salary payments from Prostate Cancer UK and the Moulton foundation grant, for his work on the CADMUS trial (ISRCTN38541912) investigating the role of multiparametric ultrasound in clinically significant prostate cancer detection. Hitachi and BK ultrasound provided hardware and software upgrades at reduced cost to facilitate this trial. MJ Connor conducts prostate cancer research funded by the Welcome Trust and University College London Hospital charity. T Loch is inventor of the ANNA/C-TRUS method and shareholder of ANNA Technologies/Deutschland, has received consultation fees from ANNA Technologies and has received teaching equipment from BK Medical. Dr. Tam has no other conflicts of interest to declare. (2020 Translational Andrology and Urology. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu